Stock listing

Mirum Pharmaceuticals, Inc.

Selected listing: 08D · HAM · EUR · DE

Mirum Pharmaceuticals, Inc. (Hamburg:08D), Health Technology. Latest release Sep 28, 2026: Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3…

08D:HAMEURDEUpdated October 2, 2026

Ticker: Hamburg:08D
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: Hamburg
Currency: EUR

Latest news from Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus

September 28, 2026

Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026

September 27, 2026

Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva

September 25, 2026

Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer

September 8, 2026

Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

August 5, 2026

All Mirum Pharmaceuticals, Inc. news →

Events

Replays

Mirum Pharmaceuticals, Inc. (MIRM) Q2 2026 Earnings Call
Wed, Aug 05, 2026 · 04:30 PM ET
Watch
Mirum Pharmaceuticals, Inc. (MIRM) Q1 2026 Earnings Call
Wed, May 06, 2026 · 04:30 PM ET
Watch
Mirum Pharmaceuticals, Inc. (MIRM) Q4 2025 Earnings Call
Wed, Feb 25, 2026 · 04:30 PM ET
Watch

Research Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. company profile

View the public company page for Mirum Pharmaceuticals, Inc. on 6ix.

Mirum Pharmaceuticals, Inc. news

Read company news and market updates connected to Mirum Pharmaceuticals, Inc..

Mirum Pharmaceuticals, Inc. investor events

Find investor webinars, events, and replay context for Mirum Pharmaceuticals, Inc..